Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Myosin Inhibition in Non-obstructive HCM
Author(s): Koji Hasegawa , Moritake Iguchi , Hiromichi Wada , et al Added: 1 week ago

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): María Salgado , Alberto Alen Andrés , Maria Fernández García , et al Added: 2 months ago

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Andrés Álvarez , Diego Manuel de la Eranueva , Manuel Sánchez , et al Added: 2 months ago

Prevention & Chronic Conditions
Non-invasive Coronary Functional Tests in ANOCA
Author(s): Nello Cambise , Angelo Giuseppe Marino , Fabio De Benedetto , et al Added: 4 months ago

Imaging & Diagnostics

Prevention & Chronic Conditions
Antithrombotics in stable CAD and AF
Author(s): Massimo Grimaldi , Bianca Rocca Added: 3 months ago

Prevention & Chronic Conditions

Anticoagulation
Author(s): Chim C Lang Added: 1 year ago
Prof Chim Lang discusses his upcoming special focus for ECR. The collection will include contributions from Dr Emily Morris, Dr John Wilding, Dr Samira Bell, Dr Bianca Rocca, and Dr Ramzi Ajjan, the collection explores the global burden of obesity, its impact on heart failure and kidney disease, and emerging therapeutic strategies—including the evolving role of GLP-1 receptor agonists. View more

Cardiovascular Kidney Metabolic
Heart Failure in 2026: Practical Therapy Lessons From ACC.26
Author(s): Felipe Martínez Added: 2 months ago
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes… View more

Heart Failure
Lipid-lowering Therapies and Lp(a)
Author(s): Stephen Nicholls , Adam J Nelson Added: 1 month ago

Prevention & Chronic Conditions
ECO 24: Increasing GLP1-RA Efficacy by Targeting Non-coding RNA
Author(s): Riccardo Panella Added: 2 years ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
The XLIMIT Trial: XLIMUS® DES Shows Non-Inferiority to Synergy™ DES
Author(s): Luca Testa Added: 2 years ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9… View more

Intervention